Our Services
Medical Information
Helpful Resources
Published on: 8/18/2026
Low-dose naltrexone (LDN) is generally taken as 0.5 mg to 4.5 mg once daily, started at the lowest dose and titrated up slowly, and it must be specially compounded because standard naltrexone tablets are 50 mg. Safe administration requires being fully opioid-free for roughly 7 to 10 days beforehand to avoid precipitated withdrawal, plus a review of liver function, pregnancy status, and interacting medications with a prescriber. Dose timing can be shifted from bedtime to morning if vivid dreams, insomnia, or headaches appear, and consistency matters more than the exact hour. There are several factors to consider, including contraindications, drug interactions, and how underlying conditions change the plan, so see below to understand the complete guidance before starting or adjusting a dose.
If you are weighing LDN because of ongoing pain, fatigue, or inflammatory symptoms, the smartest first step is to clarify what is actually driving those symptoms, since the right treatment depends entirely on the underlying cause: take a free, instant, online symptom check to organize your symptoms, understand possible explanations, and walk into your next appointment ready to ask the right questions.
Last reviewed for medical accuracy: 08/18/2026
Low-dose naltrexone (LDN) is an off-label approach increasingly used for chronic pain, autoimmune conditions and certain neurological disorders. When prescribed and administered properly, LDN can be both effective and well tolerated. Below are pharmacological guidelines—based on peer-reviewed studies and clinical best practices—to help you navigate dosing, formulation choices and safety considerations. Always work closely with your healthcare provider.
When starting LDN, patients and prescribers often weigh naltrexone compounding pharmacy liquid vs capsule. Both have pros and cons:
Bottom Line:
A gradual approach maximizes tolerability and safety. Below is a common titration schedule:
Baseline Assessment
Starting Dose
Titration Steps
Maintenance
Tip: Keep a simple diary of your daily dose, time of administration and any symptoms. Share this with your provider at follow-ups.
If you experience any of the following, stop LDN and speak to a doctor immediately:
For non-urgent symptoms, you might also consider a free, online symptom check, using the doctor approved Ubie Symptom Checker to help you decide on next steps.
Low-dose naltrexone can be a safe, practical adjunct for many chronic conditions when administered under medical supervision. Always consult your physician before making any changes to your regimen, and seek immediate care for anything life-threatening or serious.
(References)
* Kleber HD. Naltrexone. J Subst Abuse Treat. 1985;2(2):117-22. doi: 10.1016/0740-5472(85)90036-4. PMID: 3007777.
* Patten DK, Schultz BG, Berlau DJ. The Safety and Efficacy of Low-Dose Naltrexone in the Management of Chronic Pain and Inflammation in Multiple Sclerosis, Fibromyalgia, Crohn's Disease, and Other Chronic Pain Disorders. Pharmacotherapy. 2018 Mar;38(3):382-389. doi: 10.1002/phar.2086. Epub 2018 Feb 23. PMID: 29377216.
* Garcia JM, Shamliyan TA. Management of Opioid-Induced Constipation in Patients with Malignancy. Am J Med. 2018 Sep;131(9):1041-1051.e3. doi: 10.1016/j.amjmed.2018.02.038. Epub 2018 Apr 2. PMID: 29621475.
* Acharya P, Mathur M. Low-dose naltrexone in Hailey-Hailey disease: the importance of dosing. Br J Dermatol. 2020 Jul;183(1):193. doi: 10.1111/bjd.19014. Epub 2020 Apr 14. PMID: 32133619.
* Kim PS, Fishman MA. Low-Dose Naltrexone for Chronic Pain: Update and Systemic Review. Curr Pain Headache Rep. 2020 Aug 26;24(10):64. doi: 10.1007/s11916-020-00898-0. Epub 2020 Aug 26. PMID: 32845365.
* Grunvald E, Shah R, Hernaez R, Chandar AK, Pickett-Blakely O, Teigen LM, Harindhanavudhi T, Sultan S, Singh S, Davitkov P, AGA Clinical Guidelines Committee. AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. Gastroenterology. 2022 Nov;163(5):1198-1225. doi: 10.1053/j.gastro.2022.08.045. Epub 2022 Oct 20. PMID: 36273831.
* Barrett JE. A Statement on the Pharmacology of Reinstatement: Naltrexone and Relapse to Opioid Seeking. J Pharmacol Exp Ther. 2024 Mar 15;389(1):1-4. doi: 10.1124/jpet.123.001933. Epub 2024 Mar 15. PMID: 38490723.
* Spargo A, Gonser L, Faley B. Evaluation of Low-Dose Naltrexone for Chronic Pain Management. J Pain Palliat Care Pharmacother. 2025 Jun;39(2):319-322. doi: 10.1080/15360288.2025.2456279. Epub 2025 Feb 3. PMID: 39901608.
* Menge J, Evitt B. Pharmacologic interventions for alcohol use disorder. JAAPA. 2025 Jun 1;38(6):e2-e6. doi: 10.1097/01.JAA.0000000000000106. Epub 2025 May 27. PMID: 40421949.
* Byambasuren O, Atkins T, Baptista S, Glasziou P, Chakraborty S. Effect of low-dose naltrexone for long COVID: a systematic review and meta-analysis. BMJ Open. 2026 Jul 16;16(7):e111253. doi: 10.1136/bmjopen-2025-111253. Epub 2026 Jul 16. PMID: 42463201; PMCID: PMC13384149.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.